<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251145</url>
  </required_header>
  <id_info>
    <org_study_id>1182.46</org_study_id>
    <nct_id>NCT02251145</nct_id>
  </id_info>
  <brief_title>Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers</brief_title>
  <official_title>A Single Centre, Open-Label, Randomised, Parallel, Multiple Dose Comparison of the Effects of Tipranavir 500 mg and Ritonavir 100 mg or Tipranavir 750 mg and Ritonavir 200 mg Twice a Day for 11.5 Days on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate 300 mg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to characterise the effects of two dose combinations of tipranavir/ritonavir (TPV 500
      mg/RTV 100 mg and TPV 750 mg/RTV 200 mg) administered BID, on the pharmacokinetics of
      tenofovir disoproxil fumarate as well as the effects of tenofovir disoproxil fumarate on the
      pharmacokinetics of tipranavir/ritonavir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under plasma concentration time curve from 0-24 hours (AUC0-24) for tenofovir</measure>
    <time_frame>up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration time curve from 0-12hours (AUC0-12) for tipranavir/ritonavir</measure>
    <time_frame>up to 12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma at 12 hours after administration (C12h) for tenofovir</measure>
    <time_frame>up to 12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma at 12 hours after administration (C12h) for tipranavir/ritonavir</measure>
    <time_frame>up to 12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration at steady state (Cmax,ss)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration at steady state (Cmin)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residency time (MRT)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half life (T1/2)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal elimination phase, divided by F (bioavailability factor) (Vz/F)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in vital signs (pulse rate, blood pressure)</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in physical examination</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in electrocardiogram</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>tipranavir/ritonavir low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tipranavir/ritonavir high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir low dose</intervention_name>
    <arm_group_label>tipranavir/ritonavir low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir high dose</intervention_name>
    <arm_group_label>tipranavir/ritonavir high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir low dose</intervention_name>
    <arm_group_label>tipranavir/ritonavir low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir high dose</intervention_name>
    <arm_group_label>tipranavir/ritonavir high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <arm_group_label>tipranavir/ritonavir low dose</arm_group_label>
    <arm_group_label>tipranavir/ritonavir high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability and willingness to give written informed consent in accordance with
             institutional and regulatory guidelines and to comply with the investigational nature
             of the study and the related requirements

          2. Healthy males or females between 18 and 60 years of age inclusive

          3. A Body Mass Index &gt;18.5 and &lt;30 kg/m2

          4. Ability to swallow numerous large capsules without difficulty

          5. Reasonable probability for completion of the study, in the opinion of the investigator

          6. Acceptable laboratory values that indicate adequate baseline organ function are
             required at the time of screening. Laboratory values are considered to be acceptable
             if severity &lt;= Grade1 based on the AIDS Clinical Trials Group (ACTG) Division of AIDS
             (DAIDS) Grading Scale. All abnormal laboratory values &gt; Grade 1 (e.g., creatine
             phosphokinase (CPK), amylase, triglycerides) are subject to approval by the BIPI
             clinical monitor. Cholesterol &lt;= 240mg/dL at the time of screening is necessary for
             study entry

          7. Acceptable medical history, physical examination and ECG are required prior to
             entering the study

          8. Willingness to abstain from alcohol for 48 hours prior to Study Day 0 and abstain from
             alcohol for the duration of the study. In addition, Cabernet Sauvignon must not have
             been ingested within 15 days prior to Day 0 (Visit 2)

          9. Willingness to abstain from ingesting grapefruit and grapefruit juice within 15 days
             of Day 0, Visit 2 and for the duration of the study

         10. Willingness to abstain from ingesting Seville oranges, strawberries or strawberry
             extract, garlic supplements, St. John's Wort, Milk Thistle, or
             methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate,
             etc) within 72 hours of pharmacokinetic (PK) sampling days

         11. Willingness to abstain from use of tobacco products for the duration of the study

         12. Urine drug screen negative for illegal non-prescription drugs

         13. Negative HIV serology

         14. Negative for Hepatitis B surface antigen and Hepatitis C

        Exclusion Criteria:

          1. Female subjects who are of reproductive potential who:

               -  Have a positive serum B-HCG at Visit 1 or 2 or

               -  Have not been using regular oral contraception (combined oestrogen and
                  progestogen pill or progestogen only pill) for 3 months and a barrier
                  contraceptive method for at least 30 days prior to Visit 3 (Day 1) or a barrier
                  contraceptive method for at least 3 months prior to Visit 3 (Day 1) or

               -  Are not willing to use a reliable method of double-barrier contraception (such as
                  diaphragm with spermicidal cream/jelly or condoms with spermicidal foam)during
                  the trial and 30 days after completion/termination or

               -  Are breast-feeding

          2. Participation in another trial with an investigational medicine for 30 days prior to
             Day 0 (Visit 2)

          3. Ingestion of any known enzyme altering drug (such as phenothiazines, cimetidine,
             barbiturates, ketoconazole, fluconazole, rifampin, steroids, and herbal medications)
             for 30 days prior to Day 0 (Visit 2). Use of any other herbal/complementary treatment
             must be discussed in advance with the monitor and permission obtained prior to study
             entry

          4. Ingestion of grapefruit, grapefruit juice, and Cabernet Sauvignon within 15 days prior
             to Day 0 (Visit 2)

          5. Ingestion of Seville oranges, strawberries or strawberry extract, garlic supplements,
             St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee,
             tea, cola, energy drinks, chocolate, etc) within 72 hours of PK sampling days

          6. Ingestion of antibiotics within 10 days prior to Day 0 (Visit 2)

          7. Inability to comply with investigator's instructions

          8. History of gastrointestinal, hepatic, or renal disorders within 60 days

          9. History of alcohol abuse

         10. Current use of cigarettes defined as greater than 10 cigarettes per day or
             rolling/pipe tobacco equivalent

         11. Blood or plasma donations within 30 days prior to Day 0 (Visit 2)

         12. Subjects with a seated systolic blood pressure either &lt;100 mm Hg or &gt;150 mm Hg;
             resting heart rate either &lt;50 beats/min or &gt;100 beats/min

         13. Subjects with a history of any illness or allergy that, in the opinion of the
             investigator, might confound the results of the study or pose additional risk in
             administering tipranavir or ritonavir or tenofovir disoproxil fumarate to the subject

         14. Subjects who have had an acute illness within 2 weeks prior to Day 0 (Visit 2)

         15. Subjects who are currently taking any over-the-counter drug within 7 days prior to Day
             0, (Visit 2) or who are currently taking any prescription drug that, in the opinion of
             the investigator in consultation with the clinical monitor and pharmacokineticist,
             might interfere with either the absorption, distribution or metabolism of the test
             substances

         16. Hypersensitivity to tipranavir, ritonavir, or tenofovir disoproxil fumarate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

